سعر جلوورلي بلس 1/500مجم 30 قرص 2026

Egyptian Glucoryl Plus 1/500 mg film-coated tablets (glimepiride 1 mg + metformin hydrochloride 500 mg, 30 tablets), listed under Growth Pharma; fixed-dose oral antidiabetic combination.

• Hypoglycaemia is the main adverse reaction; postmarketing reports include serious hypersensitivity, haemolytic anaemia and impaired liver function (cholestasis, jaundice, hepatitis).General active-ingredient information · DailyMed (U.S. National Library of Medicine)
• Very common: nausea, vomiting, diarrhoea, abdominal pain, loss of appetite (mostly at initiation, usually resolving). Common: vitamin B12 decrease/deficiency, taste disturbance. Very rare: lactic acidosis, liver function test abnormalities/hepatitis, skin reactions.General active-ingredient information · electronic medicines compendium (emc), UK

• Hypersensitivity to glimepiride or any ingredient; history of allergic reaction to sulfonamide derivatives.General active-ingredient information · DailyMed (U.S. National Library of Medicine)
• Hypersensitivity to metformin or excipients; any acute metabolic acidosis (lactic acidosis, diabetic ketoacidosis); diabetic pre-coma; severe renal failure (GFR <30 mL/min); acute conditions that may alter renal function (dehydration, severe infection, shock); diseases that may cause tissue hypoxia (decompensated heart failure, respiratory failure, recent myocardial infarction, shock); hepatic insufficiency, acute alcohol intoxication, alcoholism.General active-ingredient information · electronic medicines compendium (emc), UK

• Can cause hypoglycaemia, sometimes severe (caution with driving/machinery); higher risk in elderly, renal impairment, poor food intake or with other glucose-lowering drugs.General active-ingredient information · DailyMed (U.S. National Library of Medicine)
• Serious hypersensitivity reactions (anaphylaxis, angioedema, Stevens-Johnson syndrome); haemolytic anaemia, especially with G6PD deficiency; label warning on increased risk of cardiovascular mortality with sulfonylureas (UGDP study).General active-ingredient information · DailyMed (U.S. National Library of Medicine)
• Lactic acidosis (very rare, serious) occurs mostly with acute worsening of renal function, cardiorespiratory illness or sepsis; temporarily stop metformin in dehydration (severe vomiting/diarrhoea, fever, reduced fluid intake). Stop before or at the time of iodinated contrast imaging and restart no sooner than 48 h after, once renal function is stable.General active-ingredient information · electronic medicines compendium (emc), UK

• Oral miconazoleSevere hypoglycaemia has been reported with concomitant use.DailyMed (U.S. National Library of Medicine)
• CYP2C9 inhibitors and inducersMay alter glimepiride plasma concentrations and glycaemic control.DailyMed (U.S. National Library of Medicine)
• ColesevelamReduces glimepiride absorption; give glimepiride at least 4 hours before colesevelam.DailyMed (U.S. National Library of Medicine)
• AlcoholAlcohol intoxication increases the risk of lactic acidosis (especially with fasting, malnutrition or hepatic impairment); avoid alcohol and alcohol-containing medicines.electronic medicines compendium (emc), UK
• Iodinated contrast agentsDiscontinue metformin before or at the time of the imaging procedure; restart no sooner than 48 h after, once renal function is re-evaluated and stable.electronic medicines compendium (emc), UK
• NSAIDs (incl. COX-2 inhibitors), ACE inhibitors, angiotensin II receptor antagonists, diuretics (especially loop diuretics)May adversely affect renal function and increase lactic acidosis risk; monitor renal function closely when starting these with metformin.electronic medicines compendium (emc), UK
• Glucocorticoids, beta-2 agonists, diureticsIntrinsic hyperglycaemic activity; more frequent blood glucose monitoring and metformin dose adjustment may be needed.electronic medicines compendium (emc), UK

• US label: available data have not identified a drug-associated risk of major birth defects or miscarriage; sulfonylureas may cause neonatal hypoglycaemia.General active-ingredient information · DailyMed (U.S. National Library of Medicine)
• A large amount of data (>1000 exposed outcomes) indicates no increased risk of congenital abnormalities or feto/neonatal toxicity after metformin exposure in the periconceptional phase and/or during pregnancy; if clinically needed, metformin can be considered during pregnancy as an addition or alternative to insulin. Metformin crosses the placenta.General active-ingredient information · electronic medicines compendium (emc), UK
• US label: monitor breastfed infants for signs of hypoglycaemia (jitteriness, cyanosis, apnoea, hypothermia, excessive sleepiness, poor feeding).General active-ingredient information · DailyMed (U.S. National Library of Medicine)
• Metformin is excreted in breast milk; no adverse effects were observed in breastfed infants, but because data are limited, breastfeeding is not recommended during treatment.General active-ingredient information · electronic medicines compendium (emc), UK

• Monitor renal function (GFR) before treatment and at least annually; monitor glycaemic control; consider vitamin B12 monitoring with long-term use.General active-ingredient information · electronic medicines compendium (emc), UK

• Glimepiride: Lowers blood glucose mainly by stimulating insulin release from functioning pancreatic beta cells.
• Metformin hydrochloride: Lowers hepatic glucose production, delays intestinal glucose absorption and improves peripheral insulin sensitivity; does not stimulate insulin secretion.